Vasculitis & polymyalgia rheumatica
Efficacy and safety of Janus kinase inhibitors in Behçet’s disease: A systematic literature review
Authors' conclusion
JAK inhibitors demonstrate promising efficacy in BD, particularly in refractory and multisystem disease. The most consistent evidence of efficacy was observed in gastrointestinal involvement, whereas data for other disease domains remain limited.
Study context
- Population
- Highly treatment-refractory BD patients with prior failure of conventional and biologic therapies
- Participants
- 99 patients17 studies
- Comparison
- Tofacitinib vs Baricitinib vs Upadacitinib
- Outcome
- Efficacy of JAKi in BD
Methodological detailsPRISMA 2020, narrative synthesis, Joanna Briggs Institute quality assessment
- PRISMA 2020
- Narrative synthesis
- Joanna Briggs Institute quality assessment
Main finding
As reported in the abstract
| Group | Overall response rate | Complete remission |
|---|---|---|
| Upadacitinib | 85.2% | 59.3% |
Upadacitinib
Overall response rate85.2%
Complete remission59.3%
Safety
- Consistent with known JAKi safety profiles: mainly mild to moderate infections, manageable laboratory abnormalities
- No clear signal for increased thrombotic events
- Follow-up was limited
Original publication
Efficacy and safety of Janus kinase inhibitors in Behçet’s disease: A systematic literature review. Semin Arthritis Rheum. Published 6 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →